Ensure Effective Access & Utilization of Scientific Communication Platforms

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from “Scientific Communication Platform Excellence: Operations, Utilization and Assessment”

STUDY OVERVIEW

Scientific communication platforms (SCPs) provide a strategic foundation for a product’s medical and scientific communications plan. However, certain faults with the SCP can impede the initial uptake or effective utilization of even the highest-quality SCPs. Identifying and establishing the right set of metrics during SCP implementation can simplify assessment of uptake and continued use.

Best Practices, LLC undertook this benchmarking research to help medical communications/publications leaders with SCP utilization, management, and evaluation. The study presents current practices around scientific communication platforms and covers how SCP platforms are utilized.

KEY TOPICS

Scientific Communication Platform Effectiveness and Faults
Scientific Communication Platform Operations
Scientific Communication Platform Access and Utilization
Scientific Communication Platform Best Practices and Pitfalls

KEY METRICS

Do scientific communication platforms meet the needs of benchmark organizations?
Why do scientific communication platforms not meet the needs of benchmark organizations?
What function or group drives/leads maintenance of the SCP?
Do benchmark companies have a Medical Operations position dedicated to their SCP?
Which internal functions have access to the SCP?
What metrics do benchmark partners use to measure the internal access of their SCP?
How do benchmark companies assess the uptake of their scientific communication platform internally?

SAMPLE KEY FINDINGS

SCP Utilization: SCP utilization is measured by a majority (61%) through level of incorporation into reactive and proactive materials for FMTs. Large Pharma particularly use this measure (88%) vs. 36% for Mid-Small (of which 36% do not measure).

METHODOLOGY

Best Practices, LLC engaged 21 Medical leaders from 21 pharma companies in this research through a benchmarking survey. Data in this study is further segmented by mid-small vs. large companies to provide in-depth insights.

Industries Profiled:
Biopharmaceutical; Pharmaceutical; Biotech; Health Care; Consumer Products; Communications; Laboratories

Companies Profiled:
Alkermes; Astellas; AstraZeneca; BELLUS Health; Boehringer Ingelheim; GlaxoSmithKline ; Gossamer Bio; Incyte; Ipsen; Merck; Nobel Biocare; Novartis; Novo Nordisk; OPEN Health; Oxford PharmaGenesis; Pfizer; Pierre Fabre; Sandoz; Spark Therapeutics; Torrent Pharmaceuticals Ltd.; UniQure

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.

Scientific Communication Platform Excellence: Operations, Utilization and Assessment

ID: 5742

Features:

Pages/Slides: 34

Published: 2022

Delivery Format: Online PDF Document

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
653A7896CFD6ACB02002588F6004001B1
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-scientific-communication-platform-excellence-operations-utilization-assessment?opendocument
18
19opendocument
2018.97.9.171
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB